Ji Hyun Kim (@writ__e) header
Ji Hyun Kim (@writ__e) profile picture

Gynecologic Oncologist National Cancer Center Korea clinical assistant professor (2024.3~), fellow (2021.3~2024.2), tweets are on my own

Joined August 2016
Ji Hyun Kim retweeted
Thrilled to co-author the Phase I study of FRฮฑ-targeting ADC Sofe-M in high-grade ovarian cancer, out now in @Annals_Oncology ๐Ÿ“ˆ 50.5% ORR across FRฮฑ levels & 58.8% at 3 mg/kg Supporting Phase 3 #FRAmework01 ๐Ÿ”— Free Share Link: authors.elsevier.com/c/1o5CVโ€ฆ @gyncsm
1
7
32
955
Ji Hyun Kim retweeted
๐Ÿšจ New lecture in #colorectal surgery: โ€œAlternatives to ostomy to protect very low colorectal anastomosesโ€ ๐Ÿ”— Watch the video on WebSurg: irc.ad/rIpm
15
72
4,100
Many young women with breast and gyn cancers go into menopause overnight from treatment: ovarian suppression, tamoxifen or an AI, oophorectomy, pelvic radiation, chemotherapy. Hot flashes, no sleep, painful sex. Some stop the pill that protects them from recurrence. What we can offer: -- Hormone therapy: not a blanket no. It can be reasonable for some survivors; but after HR+ breast cancer it is generally avoided. -- #Elinzanetant (Lynkuet): nonhormonal NK1/NK3 blocker, FDA approved for menopausal hot flashes. 120 mg at bedtime, LFTs at baseline and 3 months, check CYP3A4 interactions. Reduced hot flashes on endocrine therapy in OASIS-4; in the US that use is still under FDA review. -- Venlafaxine or gabapentin: older, effective options. -- Vaginal dryness: moisturizers and lubricants first. Ask about it every visit. Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer | New England Journal of Medicine nejm.org/doi/10.1056/NEJMoa2โ€ฆ
3
9
33
2,697
Ji Hyun Kim retweeted
Deintensification trials in ICI should be in homogeneous population and based upon good biological and pharmacological rational. Excellent discussion by @DrJNaidoo @dr_yakupergun @myESMO #esmo26
1
5
16
1,574
Ji Hyun Kim retweeted
Conclusion in One line . Trial is negative for OS . And this approach should be used only in dMMR pts . #DUO-E @myESMO #esmo26 @OncBrothers @OncoAlert
12
15
2,040
Can dMMR Endometrial Cancer Go Chemo-Free in the First Line? Can dMMR endometrial cancer go chemo-free in 1L? KEYNOTE-C93: pembrolizumab monotherapy improved PFS vs carboplatinโ€“paclitaxel; OS is still immature. Magnitude of benefit & toxicity await LBA12. @GynCancerMD @myESMO @GOG #ESMO26 #GynOnc
7
9
376
Ji Hyun Kim retweeted
Iโ€™m so sick of reviewers using ChatGPT to review papers. Itโ€™s atrocious having to respond to the same garbage from all 3 reviewers where each comment requests 5 new analyses. Just donโ€™t agree to review papers if itโ€™s too much work ๐Ÿคทโ€โ™‚๏ธ Even if you used AI to review my paper- at least ensure the asks are genuine and then choose the most pertinent/relevant comments to include in your review? Is that too much work? Iโ€™m sure journal editors recognize that this is a real problem but canโ€™t do much to rectify this issue.
22
28
3
226
30,600
Ji Hyun Kim retweeted
6,000๋ฒˆ ๋ˆ„๋ฅธ ์†์— ์˜์žฅ์ด ์™”๋‹ค ๋Œ๋„ ์•ˆ ๋œ ์•„์ด์˜ ๊ฐ€์Šด์€ ์†๊ฐ€๋ฝ ๋‘ ๊ฐœ๋กœ ๋ˆ„๋ฅธ๋‹ค. ์–ด๋ฅธ์ฒ˜๋Ÿผ ์†๋ฐ”๋‹ฅ์„ ํฌ๊ฐค ์ž๋ฆฌ๊ฐ€ ์—†๋‹ค. 1๋ถ„์— 100๋ฒˆ์ด ๋„˜๋Š”๋‹ค. 2๋ถ„๋งˆ๋‹ค ์‚ฌ๋žŒ์ด ๋ฐ”๋€๋‹ค. 60๋ถ„์ด๋ฉด 6,000๋ฒˆ์ด ๋„˜๋Š”๋‹ค. ์†์„ ๋–ผ๋„ ์•„๋ฌด๋„ ํƒ“ํ•˜์ง€ ์•Š์„ ์‹œ๊ฐ„์„ ํ•œ์ฐธ ์ง€๋‚˜์„œ์•ผ ์†์€ ๋ฉˆ์ท„๋‹ค. ์•„์ด๋Š” ๋– ๋‚ฌ๋‹คโ€ฆ ๋•€์ด ๋งˆ๋ฅด๊ธฐ ์ „์— ํ˜•์‚ฌ 2๋ช…์ด ๋“ค์–ด์™”๋‹ค. ๋ณดํ˜ธ์ž๊ฐ€ ๊ทธ ์ž๋ฆฌ์—์„œ ๊ฒฝ์ฐฐ์„ ๋ถˆ๋ €๋˜ ๊ฒƒ์ด๋‹ค. ๋’ค๋”ฐ๋ผ ๊ณผํ•™์ˆ˜์‚ฌ๋Œ€ 3๋ช…์ด ์นด๋ฉ”๋ผ๋ฅผ ๋“ค๊ณ  ๋“ค์–ด์™”๋‹ค. 77์ผ ๋’ค์—๋Š” 8๋ช…์ด ์™”๋‹ค. ๊ทธ๋•Œ ์˜์‚ฌ๋Š” ๋‹ค๋ฅธ ์•„์ด์˜ ์ˆจ๊ธธ์„ ๊ฒจ์šฐ ํ‹”์›Œ ๋†“๊ณ  ์ฒ˜๋ฐฉ์„ ๋„ฃ๋˜ ์ฐธ์ด์—ˆ๋‹ค๊ณ  ํ•œ๋‹ค. ์˜์‚ฌ๋Š” ๋ˆ๋งŒ ์•ˆ๋‹ค๋Š” ๋ง์€ ์˜ค๋ž˜๋œ ๋…ธ๋ž˜๋‹ค. ๋ˆ ๋ณด๊ณ  ์˜๋Œ€ ๊ฐ”๋‹ค๋Š” ๋ง์€ ๊ทธ ํ›„๋ ด์ด๋‹ค. ๋ˆ๋งŒ ์•„๋Š” ์‚ฌ๋žŒ์ด ์…ˆ์ด ๋น ๋ฅธ ๊ฒƒ์€ ๋งž๋‹ค. ๊ทธ๋Ÿฐ๋ฐ ์…ˆ์ด ๋น ๋ฅธ ์†์€ 60๋ถ„์„ ๊ฐ€์ง€ ์•Š๋Š”๋‹ค. 30๋ถ„์ด๋ฉด ์…ˆ์ด ๋๋‚œ๋‹ค. 60๋ถ„์€ ์…ˆ์ด ์•„๋‹ˆ๋ผ ๋ฏธ๋ จ์ด๋‹ค. ๋ฏธ๋ จ์€ ๋ˆ์ด ๋˜์ง€ ์•Š๋Š”๋‹ค. ๋ˆ๋งŒ ์•ˆ๋‹ค๋˜ ์†์ด ๋ˆ๊ณผ ๊ฐ€์žฅ ๋จผ 60๋ถ„์„ ๋ณด๋ƒˆ๊ณ , ๊ทธ 60๋ถ„์„ ๋ณด๋‚ธ ๋ฐฉ์— ์˜์žฅ์ด ์™”๋‹ค. ๋‹ค์Œ ์•„์ด๋„ 60๋ถ„์„ ๋ฐ›์„๊นŒ? ์†์€ ๊ฑฐ์ง“๋ง์„ ๋ชป ํ•œ๋‹ค. ๊ทธ๋Ÿฌ๋‚˜ ์†๋„ ๋ฐฐ์šด๋‹ค. ๊ทธ๋ณด๋‹ค ๋จผ์ € ๋ฌธ์ด ๋‹ซํž์ง€๋„ ๋ชจ๋ฅธ๋‹คโ€ฆ ์†Œ์•„์‘๊ธ‰์„ผํ„ฐ ๊ฐ„ํŒ์„ ๋‚ด๋ฆฌ์ž๋Š” ๋ง์ด ํ•™ํšŒ์—์„œ ๋‚˜์™”๋‹ค. 6,000๋ฒˆ์€ ์…€ ์ˆ˜ ์žˆ๋‹ค. ํ•˜์ง€๋งŒ ์˜ค์ง€ ์•Š์„ ์†์€ ์…€ ์ˆ˜๊ฐ€ ์—†๋‹ค.
์ถœ์„ธํ•œ ์˜์‚ฌ๋Š” ์˜์‚ฌ๋ฅผ ๊ทธ๋งŒ๋‘” ์‚ฌ๋žŒ์ด๋‹ค ๋ˆ ์ž˜ ๋ฒŒ๊ณ  ์ถœ์„ธํ•˜๋ ค๊ณ  ๊ณต๋ถ€๋งŒ ํ•œ ์ธ๊ฐ„๋“ค์ด๋ผ๋Š” ๋ง์ด ๋–จ์–ด์ง€๊ณ  ํฐ ๊ฐ€์šด๋“ค์˜ ์–ผ๊ตด์ด ๊ตณ๋Š”๋‹ค. ๋‚˜๋Š” ๊ทธ ์–ผ๊ตด๋“ค์—๊ฒŒ์„œ ๋‹ค๋ฅธ ๊ฒƒ์„ ๋ณธ๋‹ค. ์–ด๋ฅธ๋“ค ๋ง์„ ์ œ์ผ ์ž˜ ๋“ค์€ ์•„์ด๋“ค์ด๋‹ค. ๊ณต๋ถ€ํ•˜๋ผ๋‹ˆ๊นŒ ํ–ˆ๊ณ , ์ž˜ํ•˜๋ฉด ์˜๋Œ€์— ๊ฐ€๋ผ๋‹ˆ๊นŒ ๊ฐ”๋‹ค. ๊ทธ ๊ฐ€์šด์€ ํ•™์› ์•ž์— ์‹œ๋™์„ ์ผœ ๋†“๊ณ  ๊ธฐ๋‹ค๋ฆฌ๋˜ ๋ถ€๋ชจ๋“ค์ด ์ž…ํžŒ ์˜ท์ด๋‹ค. ๊ณต๋ถ€๋งŒ ํ•œ ๊ฒƒ์ด ์ฃ„๋ผ๋ฉด ๊ณต๋ฒ”์ด ๋„ˆ๋ฌด ๋งŽ๋‹ค. ์ถœ์„ธ๋ผ๋Š” ๋ง์€ ๋” ์–ด์ƒ‰ํ•˜๋‹ค. ์ถœ์„ธ๋ž€ ํ•˜๋˜ ์ผ์„ ๋†“๊ณ  ๋” ๋†’์€ ์ž๋ฆฌ๋กœ ์˜ฎ๊ฒจ ๊ฐ€๋Š” ๊ฒƒ์ธ๋ฐ, ์˜์‚ฌ๋Š” 30๋…„์ด ์ง€๋‚˜๋„ ์ฒซ๋‚  ๊ทธ ์ž๋ฆฌ์—์„œ ๊ฐ™์€ ์ผ์„ ํ•œ๋‹ค. ์ถœ์„ธํ•œ ์˜์‚ฌ๋Š” ๋Œ€๊ฐœ ์˜์‚ฌ๋ฅผ ๊ทธ๋งŒ๋‘” ์‚ฌ๋žŒ์ด๋‹ค. ๋ˆ ์ชฝ์€ ๋” ์žฌ๋ฏธ์žˆ๋‹ค. ์ด ๋“œ๋ผ๋งˆ์—์„œ ๋ˆ ์–˜๊ธฐ๋Š” ๋ˆ์„ ์ข‡๋Š” ์†Œ๊ฐœ์†Œ ์†Œ์žฅ์ด ๋งก๊ณ  ์œค๋ฆฌ ์–˜๊ธฐ๋Š” ์˜์‚ฌ๊ฐ€ ๋งก๋Š”๋‹ค. ๋ถ„์—…์ด ๊น”๋”ํ•˜๋‹ค. ๋ˆ์„ ๋” ๋ฒŒ๊ณ  ์‹ถ์€ ๋งˆ์Œ์€ ์ฒด์˜จ ๊ฐ™์•„์„œ ๋ˆ„๊ตฌ์—๊ฒŒ๋‚˜ ์žˆ๊ณ  ์—†์œผ๋ฉด ํฐ์ผ ๋‚œ๋‹ค. ์„ธ์ƒ์€ ์˜์‚ฌ์—๊ฒŒ๋Š” ์œ ๋… ์ฒด์˜จ๊ณ„๋ฅผ ๋“ค์ด๋Œ€๊ณ  ์—ด์ด ์žˆ๋‹ค๊ณ  ํ•œ๋‹ค. ๋‚˜๋„ 30๋…„์งธ ๋ฏธ์—ด์ด๋‹ค. ๊ทธ ๋•์— ์˜ค๋Š˜๋„ ์ง„๋ฃŒ์‹ค์— ์žˆ๋‹ค.
17
290
17
795
71,698
Highly recommend reading these three papers in advance! Also subscribe to our monthly newsletter here- oncologybg.com/newsletters/
Are you heading to #ESMO26 in Madrid? Donโ€™t forget to attend the ESMO-MCBS special session on Friday afternoon! @oncology_bg will talk on how to read a clinical trial! cslide.ctimeetingtech.com/esโ€ฆ
1
8
49
3,200
Ji Hyun Kim retweeted
๐Ÿ”ด Mobilisation des lycรฉens : "Je ne veux pas รชtre reprรฉsentant de quoi que ce soit, moi je suis un produit des rรฉseaux sociaux, j'en suis conscient. Dรจs que la vibe des blocus disparaitra, je disparaitrai avec", affirme Elwan dans #LaGrandeConfrontation
315
4,365
555
34,009
2,554,140
๐Ÿ†•article in press: Efficacy of cryotherapy in preventing taxane-induced neuropathy: The CryoPac randomised controlled trial doi.org/10.1016/j.annonc.202โ€ฆ
5
10
2,233
๐Ÿšจ NEW ASCO 2026 GUIDELINE: Recurrent Ovarian Cancer A practical treatment algorithm worth saving ๐Ÿ‘‡ PLATINUM-SENSITIVE recurrence โ†’ Platinum doublet remains backbone: โ€ข Carboplatin + PLD โ€ข Carboplatin + paclitaxel โ€ข Carboplatin + gemcitabine โ†’ Bevacizumab may be added, followed by maintenance bevacizumab โ†’ Do NOT add trabectedin to PLD PLATINUM-RESISTANT / REFRACTORY โญ FRฮฑ-high: Mirvetuximab soravtansine = strong recommendation Other options: โ€ข PLD โ€ข Paclitaxel โ€ข Bevacizumab + chemotherapy โ€ข Relacorilant + nab-paclitaxel โ€ข Gemcitabine SURGERY Secondary cytoreduction is not routinely recommended based on current evidence, but may be discussed when complete gross resection is highly achievable. HIPEC Evidence remains insufficient for a routine recommendation. Key message: Recurrent ovarian cancer is becoming increasingly biomarker-driven and patient-selected, especially in platinum-resistant disease. @ASCO @JCO_ASCO @OncoAlert #OvarianCancer #GynOnc #Oncology
4
40
101
5,397
๐Ÿงฌ KEYLYNK-001 (Lancet Oncol 2026) Does adding pembrolizumab to chemo + olaparib help first-line BRCA non-mutated ovarian cancer? doi:10.1016/S1470-2045(26)00223-8
1
1
191
๐Ÿ“Š Progression-free survival: Pembro+ola 22.1 vs 14.6 mo HR 0.68, p<0.0001 Pembro alone (CPSโ‰ฅ10): HR 0.95 Overall survival: HR 1.04
1
40
๐Ÿ’ก Pembro alone failed โ†’likely a PARPi maintenance benefit, not IO. No olaparib-only arm to prove pembro adds more.
22
๋…ผ๋ฌธ PDF๋งŒ ์Œ“์ด๊ณ , ์ฝ๊ณ  ๋‚˜์„œ๋„ ๋‚จ๋Š” ๊ฒŒ ์—†๋‹ค๋ฉด ์ด 3๊ฐœ ์ €์žฅํ•ด๋‘๋ฉด ๋จ. ๊ด€๋ จ ๋…ผ๋ฌธ ์ฐพ๊ธฐ โ†’ ๋ง‰ํžŒ ๋‚ด์šฉ ์งˆ๋ฌธํ•˜๊ธฐ โ†’ ๊ทผ๊ฑฐ์™€ ๋ฉ”๋ชจ ๋‚จ๊ธฐ๊ธฐ. ๊ด€์‹ฌ ๋ถ„์•ผ๋ฅผ ์ฒ˜์Œ ๊ณต๋ถ€ํ•˜๊ฑฐ๋‚˜ ์—ฐ๊ตฌ ์ฃผ์ œ๋ฅผ ํƒ์ƒ‰ํ•  ๋•Œ ์“ฐ๋Š” ์กฐํ•ฉ์ž„. 1. ResearchRabbit ๋…ผ๋ฌธ ํ•˜๋‚˜๋ฅผ ๊ธฐ์ค€์œผ๋กœ ๋น„์Šทํ•œ ์—ฐ๊ตฌ์™€ ์•ž๋’ค๋กœ ์ด์–ด์ง€๋Š” ์—ฐ๊ตฌ๋ฅผ ์ฐพ์•„๋ณด๊ธฐ. โ€œ์ด ๋…ผ๋ฌธ ๋‹ค์Œ์—๋Š” ๋ญ˜ ์ฝ์–ด์•ผ ํ•˜์ง€?โ€ ์‹ถ์„ ๋•Œ ์“ฐ๊ธฐ ์ข‹์Œ. ๊ธฐ๋ณธ ๊ฒ€์ƒ‰๊ณผ ๋…ผ๋ฌธ ๋ชจ์Œ ๊ธฐ๋Šฅ์€ ๋ฌด๋ฃŒ์ž„. researchrabbit.ai/ 2. Gemini Notebook โ€” ๊ธฐ์กด NotebookLM ๋…ผ๋ฌธ PDF๋ฅผ ๋„ฃ๊ณ  ์—ฐ๊ตฌ ๋ฌธ์ œยท๋ฐฉ๋ฒ•ยท๊ฒฐ๊ณผ๋ฅผ ์งˆ๋ฌธํ•˜๊ธฐ. ์ดํ•ด๊ฐ€ ์•ˆ ๋˜๋Š” ๋ถ€๋ถ„์„ ์ขํ˜€ ๋ฌป๊ณ , ๋‹ต๋ณ€์— ๋ถ™์€ ์ถœ์ฒ˜๋กœ ์›๋ฌธ์„ ํ™•์ธํ•  ๋•Œ ์“ฐ๋ฉด ๋จ. notebook.google/ 3. Zotero ๋…ผ๋ฌธ๊ณผ ๋ฉ”๋ชจ๋ฅผ ํ•จ๊ป˜ ๋ณด๊ด€ํ•˜๊ณ , ๋ฐ‘์ค„ ์นœ ๋ถ€๋ถ„์„ ์ถœ์ฒ˜๊ฐ€ ์—ฐ๊ฒฐ๋œ ๋…ธํŠธ๋กœ ๋ชจ์œผ๊ธฐ. ๋‚˜์ค‘์— โ€œ์ด ์„ค๋ช…์ด ์–ด๋А ๋…ผ๋ฌธ์— ์žˆ์—ˆ์ง€?โ€๋ฅผ ๋‹ค์‹œ ์ฐพ์„ ๋•Œ ์“ฐ๊ธฐ ์ข‹์Œ. zotero.org/ ๋…ผ๋ฌธ ์ฐพ๊ธฐ โ†’ ์งˆ๋ฌธํ•˜๋ฉฐ ์ฝ๊ธฐ โ†’ ์›๋ฌธ ๊ทผ๊ฑฐ์™€ ๋ฉ”๋ชจ ์ €์žฅํ•˜๊ธฐ. ์ฒ˜์Œ์—๋Š” ๋…ผ๋ฌธ ํ•œ ํŽธ์—์„œ โ€˜๋ฌด์Šจ ๋ฌธ์ œ๋ฅผ ํ’€์—ˆ๋Š”์ง€, ์–ด๋–ป๊ฒŒ ํ’€์—ˆ๋Š”์ง€, ์–ด๋””๊นŒ์ง€ ํ™•์ธํ–ˆ๋Š”์ง€โ€™๋งŒ ๋‚จ๊ฒจ๋ณด๋ฉด ๋จ. AI ์š”์•ฝ์„ ๋ชจ์œผ๋Š” ๊ฒƒ๋ณด๋‹ค, ๋‚ด๊ฐ€ ์„ค๋ช…ํ•  ์ˆ˜ ์žˆ๋Š” ๋‚ด์šฉ๊ณผ ๋‹ค์‹œ ํ™•์ธํ•  ๊ทผ๊ฑฐ๋ฅผ ํ•จ๊ป˜ ๋‚จ๊ธฐ๋Š” ๋ฐ ์“ฐ๋ฉด ์ข‹์Œ.
115
7
327
28,479
Historically, medical research has relied heavily on male participants, with findings often generalized to women and children. If womenโ€™s health is discussed at all, itโ€™s largely framed around reproduction. This special issue of Science highlights the research that is seeking to close the critical gaps in womenโ€™s health. Learn more: scim.ag/4hy8ACT
37
452
45
1,018
99,603